Development asset linked to Mineralys Therapeutics in public FDA and regional records.
pharma · Hypertension · Uncontrolled and Resistant Hypertension · MLYS
Mineralys Therapeutics
Mineralys Therapeutics drug portfolio — 6 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Radnor, USA HQ
2020 Founded
106 Employees
Public company Type
MLYS · NYSE Ticker
Company details
- Status
- Public
- HQ
- Radnor, USA
- Founded
- 2020
- Employees
- 106
- Programs
- 7
- Drugs
- 6
- Patents
- 0
Mineralys Therapeutics pipeline
Portfolio lens on 6 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Mineralys Therapeutics drug portfolio — 6 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Molecular target: Adrenocorticotropic hormone receptor.
- Target
- Adrenocorticotropic hormone receptor
- Mechanism
- Melanocortin receptor 2 agonist
-
insulin aspart
Alimentary tract and metabolism (A10)US regulatory status: approved. Molecular target: Insulin receptor.
- Target
- Insulin receptor
- Mechanism
- Insulin receptor agonist
-
Development asset linked to Mineralys Therapeutics in public FDA and regional records.
-
Development asset linked to Mineralys Therapeutics in public FDA and regional records.
-
Development asset linked to Mineralys Therapeutics in public FDA and regional records.